Japanese initiative for education in pharmaceutical medicine and clinical research training
Journal Title: Journal of Medicines Development Sciences - Year 2016, Vol 2, Issue 2
Abstract
Development of new medicines has become increasingly difficult with less possibility of success in seeds-finding and ever rising operational costs. Failure to comply with ethical standards for human research protection also erodes social trust in clinical development. In order to develop competence of professionals in medicines development such as clinical investigators and drug development scientists, a variety of educational courses and training programs have been developed and executed worldwide. As Japan is no exception and shares the same concerns, significant governmental and non-governmental efforts have been made to invest in the development of academic educational courses and adherence to international standards. This article introduces examples of the adoption of technologies to realize a user-friendly and sustainable learning management as well as an adaptation of syllabuses and core curricula to meet international standards in the era of global medicines development.
Authors and Affiliations
Akiko Kishi, Ichiro Uchida, Daisuke Koide and Kyoko Imamura
Keywords
Related Articles
- EP ID EP679240
- DOI -
- Views 184
- Downloads 0
Models for accessing biomedical innovation in Asia
Asian countries are striving to transition into innovation-driven economies, and healthcare is a key sector on government agendas. Strong funding at academic institutions, high-impact publications, state-of-the-art clini...
A systems approach to enhance clinical research and medicines development
The biopharmaceutical industry has traditionally been the key link between basic biomedical discovery and novel medicines. Today, the industry faces numerous challenges including the broad agreement that the current clin...
The European lead factory—an experiment in collaborative drug discovery
The European Lead Factory (ELF) is a unique collaborative public–private partnership aiming to deliver innovative drug discovery starting points and improving the value generated by ultra-High Throughput Screening (uHTS)...
Investigative safety strategies to improve success in drug development
Understanding and reducing attrition rate remains a key challenge in drug development. Preclinical and clinical safety issues still represent about 40% of drug discontinuation, of which cardiac and liver toxicities are t...
European initiatives for better training in medicines development
In the last decade, the environment for medicines development has undergone unprecedented change, including: a shift from predominantly big Pharma to one of extensive industry–academia and SME partnerships and collaborat...